Overview

• This landmark investment aims to rectify chronic underfunding that has left female-specific conditions beyond oncology with just 1% of global health R&D budgets.
• Seventy percent of the new funds will go directly to research and product development, mobilizing support for more than 40 innovations.
• Priority areas include obstetric care and maternal immunization, maternal nutrition, gynecological health, contraceptive innovation, and sexually transmitted infections.
• Early pilots include AI-powered portable ultrasounds for low-resource settings and a discreet injectable contraceptive with a six-month duration now in clinical trials.
• Foundation leaders are calling on governments, philanthropies, and private investors to co-invest and ensure breakthroughs reach women worldwide.